<DOC>
	<DOCNO>NCT02584504</DOCNO>
	<brief_summary>Primary Objective : To demonstrate reduction low-density lipoprotein cholesterol ( LDL-C ) alirocumab administration add-on therapy non-statin lipid modifying therapy ( LMT ) include diet therapy alone low strength statin comparison placebo 12 week treatment patient hypercholesterolemia . Secondary Objective : - To evaluate effect two treatment regimen alirocumab lipid parameter : apolipoprotein B ( Apo-B ) , non-high-density lipoprotein cholesterol ( non HDL-C ) , total cholesterol ( TC ) , lipoprotein ( ) [ Lp ( ) ] , high-density lipoprotein cholesterol ( HDL-C ) , triglyceride ( TG ) , apolipoprotein A-1 ( Apo A-1 ) . - To evaluate safety tolerability alirocumab administration . - To evaluate development anti-alirocumab antibody . - To evaluate pharmacokinetic pharmacodynamic profile alirocumab administration . - To evaluate long-term safety patient receive open-label alirocumab administration .</brief_summary>
	<brief_title>Efficacy Safety Alirocumab Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy Lowest Strength Statin</brief_title>
	<detailed_description>The duration study per patient approximately 79 week consist run-in period ( 4 week ) , screen period ( 3 week ) , double-blind treatment period ( 12 week ) , open-label treatment period ( 52 week ) , follow-up period ( 8 week ) .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Patients hypercholesterolemia ( heterozygous familial hypercholesterolemia [ heFH ] nonfamilial hypercholesterolemia [ nonFH ] ) receive non statin LMTs low strength statin . Exclusion criterion : LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) screen visit ( Week 3 ) patient heFH patient nonFH history document coronary heart disease . LDLC &lt; 120 mg/dL ( &lt; 3.10 mmol/L ) screen visit ( Week 3 ) patient nonFH patient history document disease risk factor classify primary prevention category III . Not stable dose LMTs ( include diet therapy alone ) runin period screen period . Fasting serum TG &gt; 400 mg/dL ( &gt; 4.52 mmol/L ) screening period . Systolic blood pressure ( BP ) &gt; 160 mmHg diastolic BP &gt; 100 mmHg runin visit ( Week 7 ) screen visit ( Week 3 ) randomization visit ( Week 0 ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>